116 related articles for article (PubMed ID: 30863125)
1. Erratum: Retrospective analysis of relationships among the dose regimen, trough concentration, efficacy, and safety of teicoplanin in Chinese patients with moderate-severe Gram-positive infections [Corrigendum].
Infect Drug Resist; 2019; 12():431. PubMed ID: 30863125
[TBL] [Abstract][Full Text] [Related]
2. Retrospective analysis of relationships among the dose regimen, trough concentration, efficacy, and safety of teicoplanin in Chinese patients with moderate-severe Gram-positive infections.
Zhou L; Gao Y; Cao W; Liu J; Guan H; Zhang H; Shi Y; Lv W; Cheng L
Infect Drug Resist; 2018; 11():29-36. PubMed ID: 29379306
[TBL] [Abstract][Full Text] [Related]
3. Corrigendum.
Paediatr Child Health; 2015; 20(8):466-7. PubMed ID: 26744561
[TBL] [Abstract][Full Text] [Related]
4. ERRATUM.
Int J Bioprint; 2020; 6(4):309. PubMed ID: 33102924
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic Drug Level Monitoring of Teicoplanin in Korean Pediatric Patients with Normal versus Impaired Renal Function.
Choi JS; Kim JM; Kim D; Kim SH; Cho H; Park HD; Lee SY; Kang CI; Kim YJ
J Korean Med Sci; 2020 Nov; 35(46):e376. PubMed ID: 33258328
[TBL] [Abstract][Full Text] [Related]
6. Clinical efficacy and safety in patients treated with teicoplanin with a target trough concentration of 20 μg/mL using a regimen of 12 mg/kg for five doses within the initial 3 days.
Ueda T; Takesue Y; Nakajima K; Ichiki K; Ishikawa K; Takai Y; Yamada K; Tsuchida T; Otani N; Takahashi Y; Ishihara M; Takubo S; Ikeuchi H; Uchino M; Kimura T
BMC Pharmacol Toxicol; 2020 Jul; 21(1):50. PubMed ID: 32641110
[TBL] [Abstract][Full Text] [Related]
7. Loading dose required to achieve rapid therapeutic teicoplanin trough plasma concentration in patients with multidrug-resistant gram-positive infections.
Wang JT; Liao HI; Wu Lin FL; Chang SC
Basic Clin Pharmacol Toxicol; 2012 May; 110(5):416-20. PubMed ID: 22309355
[TBL] [Abstract][Full Text] [Related]
8. Factors on trough teicoplanin levels, associations between levels, efficacy and safety in patients with gram-positive infections.
Wang T; Li N; Hu S; Xie J; Lei J; Wang Y; Zheng X; Xing J; Dong Y
Int J Clin Pharmacol Ther; 2015 May; 53(5):356-62. PubMed ID: 25828639
[TBL] [Abstract][Full Text] [Related]
9. Teicoplanin use in adult patients with haematological malignancy: Exploring relationships between dose, trough concentrations, efficacy and nephrotoxicity.
Byrne CJ; Egan S; Fennell JP; O'Byrne P; Enright H; Deasy E; Ryder SA; D'Arcy DM; McHugh J
Int J Antimicrob Agents; 2015 Oct; 46(4):406-12. PubMed ID: 26228465
[TBL] [Abstract][Full Text] [Related]
10. Erratum: Efficacy and safety of indacaterol/glycopyrronium in Japanese patients with COPD: a subgroup analysis from the SHINE study [Corrigendum].
Int J Chron Obstruct Pulmon Dis; 2017; 12():231. PubMed ID: 28138232
[TBL] [Abstract][Full Text] [Related]
11. Development of initial loading procedure for teicoplanin in critically ill patients with severe infections.
Matsumoto K; Kanazawa N; Watanabe E; Yokoyama Y; Fukamizu T; Shimodozono Y; Maeda C; Yasuda T; Kakihana Y; Ikawa K; Morikawa N; Takeda Y
Biol Pharm Bull; 2013; 36(6):1024-6. PubMed ID: 23727923
[TBL] [Abstract][Full Text] [Related]
12. Erratum: Efficacy and safety of icotinib in patients with brain metastases from lung adenocarcinoma [Corrigendum].
Onco Targets Ther; 2017; 10():1709. PubMed ID: 28356758
[TBL] [Abstract][Full Text] [Related]
13. Enhanced loading dose of teicoplanin for three days is required to achieve a target trough concentration of 20 μg/mL in patients receiving continuous venovenous haemodiafiltration with a low flow rate.
Ueda T; Takesue Y; Nakajima K; Ichiki K; Ishikawa K; Yamada K; Tsuchida T; Otani N; Ide T; Takeda K; Nishi S; Takahashi Y; Ishihara M; Takubo S; Ikeuchi H; Uchino M; Kimura T
J Infect Chemother; 2022 Feb; 28(2):232-237. PubMed ID: 34844858
[TBL] [Abstract][Full Text] [Related]
14. Erratum: A Phase II/III, randomized, double-masked, vehicle-controlled, dose-ranging study of the safety and efficacy of OTX-101 in the treatment of dry eye disease [Corrigendum].
Clin Ophthalmol; 2019; 13():215. PubMed ID: 30774301
[TBL] [Abstract][Full Text] [Related]
15. Erratum: A Phase II/III, randomized, double-masked, vehicle-controlled, dose-ranging study of the safety and efficacy of OTX-101 in the treatment of dry eye disease [Corrigendum].
Clin Ophthalmol; 2018; 12():2637. PubMed ID: 30587910
[TBL] [Abstract][Full Text] [Related]
16. Erratum: Annual biologic treatment cost for new and existing patients with moderate to severe plaque psoriasis in Greece [Corrigendum].
Clinicoecon Outcomes Res; 2015; 7():161. PubMed ID: 25834459
[TBL] [Abstract][Full Text] [Related]
17. High-dose regimen to achieve novel target trough concentration in teicoplanin.
Ueda T; Takesue Y; Nakajima K; Ichki K; Wada Y; Komatsu M; Tsuchida T; Takahashi Y; Ishihara M; Kimura T; Uchino M; Ikeuchi H
J Infect Chemother; 2014 Jan; 20(1):43-7. PubMed ID: 24462424
[TBL] [Abstract][Full Text] [Related]
18. Erratum: Eribulin for the treatment of metastatic breast cancer: an update on its safety and efficacy [Corrigendum].
Int J Womens Health; 2015; 7():403. PubMed ID: 25960676
[TBL] [Abstract][Full Text] [Related]
19. An assessment of teicoplanin use and monitoring serum levels in a Chinese teaching hospital.
Dong YL; Dong HY; Hu SS; Wang X; Wei YX; Wang MY; Dong WH; Yao HP; You HS; Xing JF
Int J Clin Pharmacol Ther; 2011 Jan; 49(1):14-22. PubMed ID: 21176720
[TBL] [Abstract][Full Text] [Related]
20. Erratum: The efficacy and safety of add-on 0.1% brimonidine tartrate preserved with sodium chlorite in on-treatment Japanese normal-tension glaucoma patients [Corrigendum].
Clin Ophthalmol; 2015; 9():1365. PubMed ID: 26229429
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
